PALI - palisadebio.com Total Debt to Capital

Palisade Bio, Inc. (PALI) develops gut rehabilitation tools for post-surgical recovery, leveraging patented technologies to achieve high profitability. The firm's environmental footprint is minimal, as its biotech developments do not harm nature. This chart of share prices reflects a total debt-to-equity ratio of 0.00. The reliability of drug delivery to clinics is ensured by strict temperature control during transportation.

PALI: Palisade Bio Total Debt to Capital 07/04/2022 - 10/29/2026

Analytical breakdowns for Palisade Bio, Inc.

- price and consensus price forecast:

Price Chart Palisade Bio, Inc.|PALI - Forecast Levels Chart

- market capitalization statistics:

Market Capitalization Palisade Bio|PALI - Value Adjusted for Debt and Cash

- book capitalization indicators:

Book Value per Share Palisade Bio|PALI - Book Capitalization|Market Value to Book Value Ratio palisadebio.com|PALI - Aggregate Asset Value

- company total debt and liquidity indicators:

Basic company analysis:Palisade Bio, Inc.

For Palisade Bio, Inc. (PALI), reliance on foreign production sites makes financial stability critical in the event of logistical or geopolitical shocks. By analyzing changes in the leverage ratio, an investor assesses the proportion of debt to equity, which determines the company's ability to service its obligations without compromising operational activities amid raw material shortages or trade restrictions.

Competitor analysis for Palisade Bio, Inc.

Debt to Equity Phathom Pharmaceuticals, Inc.|Terns Pharma - Aggregate Debt to Equity|Total Debt to Capital IRWD|CURX (curanexpharma.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital IMRN (Immuron)|Total Debt to Capital evokepharma.com EVOK|ENTO - Debt to Equity|All Debt to Shareholders' Equity Ratio RDHL (RedHill Biopharma)|Jaguar Animal Health (JAGX) - Debt to Equity|Total Debt to Equity Ratio Biora Therapeutics, Inc|MORF (Morphic Holding, Inc.) - Total Debt to Capital